80 results
8-K
EX-99.1
ANIK
Anika Therapeutics Inc.
13 Mar 24
Anika Reports Fourth Quarter and Year-End 2023 Financial Results
4:10pm
and Recent Business Highlights
Strengthening Leadership Position in OA Pain ManagementAchieved record annual revenues of $102 million in OA Pain Management
8-K
EX-99.1
ANIK
Anika Therapeutics Inc.
2 Nov 23
Anika Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance on Growing Momentum Across the Business
4:11pm
in 2023 on the safe and effective use of Anika’s full Joint Preservation and Restoration product portfolio.
Increasing Leadership in OA Pain
8-K
EX-99.1
8kkctleka9x0
21 Sep 23
Regulation FD Disclosure
7:55am
8-K
EX-99.1
9flreu5adek5k5j9
8 Aug 23
Anika Reports Second Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
s1u86k 5u4lclug7ic4
9 May 23
Anika Reports First Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
7en52y br0p1sr2u
13 Apr 23
Anika Enters Into Cooperation Agreement with Caligan Partners
5:20pm
PRRN14A
lvz5mfeq3 kfcelv7y06
6 Apr 23
Revised preliminary proxy statement filed by non-management
5:24pm
PRER14A
ba9bmqkk
5 Apr 23
Preliminary revised proxy
11:19am
PREC14A
o9p2zo p4grvf
30 Mar 23
Preliminary proxy with contested solicitation
5:12pm
8-K
EX-99.1
oyuof9dj kiuh24f
8 Nov 22
Anika Reports Third Quarter Fiscal 2022 Financial Results
4:10pm
DEFA14A
340bw 292y
1 Jun 22
Additional proxy soliciting materials
12:08pm